
|Videos|April 10, 2014
The Utility of the CA 19-9 Test in Patients With Pancreatic Cancer
Author(s)Wen Wee Ma, MBBS
Wen Wee Ma, MBBS, associate professor of oncology, Department of Medicine, Roswell Park Cancer Institute, discusses the utility of CA 19-9 in patients with pancreatic cancer.
Advertisement
Clinical Pearls
Wen Wee Ma, MBBS, associate professor of oncology, Department of Medicine, Roswell Park Cancer Institute, discusses the utility of CA 19-9 in patients with pancreatic cancer.
- CA 19-9 is a cancer marker that can be measured in the blood and is elevated in 60-70% of patients with pancreatic cancer
- High levels of CA 19-9 in a patient who does not otherwise have clinical features of pancreatic cancer is not helpful in obtaining a diagnosis
- CA 19-9 is primarily used in monitoring treatment response
VisitPancreatic Cancer ActionorRoswell Park Cancer Institute
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Gut Health & Myeloma: How Bacteria May Predict Transplant Success With Pooja Phull, MD
5










































